Oral Isobutyramide Therapy in Patients with Thalassemia Intermedia: Results of a Phase II Open Study

ABSTRACT A pilot phase II open study on 12 patients with thalassemia intermedia (7 men, 5 women; age 31 ± 2.0 years SE) treated with oral isobutyramide, a derivative of butyric acid (150 mg/kg body wt/day), was performed in order to evaluate the effect of this compound in stimulating hemoglobin F (H...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cells, molecules, & diseases molecules, & diseases, 2000-02, Vol.26 (1), p.105-111
Hauptverfasser:	Domenica Cappellini, Maria, Graziadei, Giovanna, Ciceri, Laura, Comino, Alessia, Bianchi, Paolo, Porcella, Antonella, Fiorelli, Gemino
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Amides - administration & dosage Amides - pharmacology Amides - standards Analysis of Variance Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Antineoplastic Agents - standards beta-Thalassemia - blood beta-Thalassemia - drug therapy butyrates Cell Size Drug Evaluation European Continental Ancestry Group Female Fetal Hemoglobin - analysis Fetal Hemoglobin - drug effects Genotype Hb switch Hb-F induction Humans isobutyramide Male Pilot Projects thalassemia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!